FINANCING OF PRIVATE BIOTECHNOLOGY COMPANIES: $306.3M

Company

Location

Date

Amt. (M)

Details

Acologix Inc.

Hayward, Calif.

2/14/06

$4.5

The company added $4.5M to the $25.3M raised in its Series C round in December 2005; new investors joined existing investors in the second closing

ARYx
Therapeutics
Inc.

Fremont, Calif.

2/7/06

$30.4

The Series E financing was led by Ascent Biomedical Ventures and included existing investors MPM Capital, Nomura Phase4 Ventures, OrbiMed, Merlin BioMed, JAFCO Life Science Investments, Scottish Widows Investment Partnership, Montreux Equity Partners and Novel Bioventures

Cadence
Pharmaceuticals
Inc.

San Diego

2/22/06

$60.8

A $53.8M equity financing was led by Frazier Healthcare Ventures, and included new investors existing investors Domain Associates, ProQuest Versant Ventures and Technology Partners and Investments, BB Biotech Ventures and CDIB BioScience Venture Management; another $7M was raised in a debt financing

Catalyst
Biosciences
Inc.

South San Francisco

2/9/06

$30

The Series B financing was led by Morgenthaler Ventures and included HealthCare Ventures and previous investors Sofinnova Ventures, Burrill & Co., RCT BioVentures and Novartis Venture Fund

Chaperone
Technologies
Inc.

Scranton, Pa.

2/8/06

$0.1

The investment was made by the Life Sciences Greenhouse of Central Pennsylvania

CODA
Genomics Inc.

Irvine, Calif.

2/28/06

$1.6

The Series B financing was led by the Life Science Angels, and included Monitor Ventures and previous investors from the Tech Coast Angels

Cytomics
Systems

Gif-sur-Yvette, France

2/28/06

€10 ($11.9)

The Series B financing was led by Edmond de Rothschild Investment Partners and Truffle Venture, and included Societe Generale Asset Management Alternative Investments

FASgen Inc.

Baltimore

2/3/06

$0.5

The unsolicited financing was provided by a new investor

Inflabloc
Pharmaceuticals
Inc.

Salt Lake City

2/9/06

$6

The Series C financing was disclosed along with Inflabloc's merger with MantiCore Pharmaceuticals Inc.; Friedli Corporate Finance and vSpring Capital co-led the financing

Lectus
Therapeutics
Ltd.

Bristol, UK

2/13/06

£8.2 ($14.3)

The Series A funding was led by Sofinnova Partners and Quester; also participating were Takeda Research Investment Inc. and Astellas Venture Management

Microbia Inc.

Cambridge, Mass.

2/27/06

$75

The Series E financing was led by Sigma Capital Management LLC, and included Jennison Associates, Maverick Capital and others

PolyMedix
Inc.

Philadelphia

2/22/06

$21.2

In connection with deal, PolyMedix completed a merger and plans to list its stock; Fordham Financial was placement agent (2/22)

Precision
Therapeutics
Inc.

Pittsburgh

2/20/06

$20

Quaker BioVentures Inc. was lead investor in the Series B financing; also participating were Birchmere Ventures, Adams Capital Management, Draper Triangle Ventures and TVM Techno Venture Management

Somanta Inc.

Irvine, Calif.

2/1/06

$5.9

The Series A financing was completed along with its reverse merger with the public company Hibshman Optical Corp.; SCO Securities LLC was placement agent

StemPath Inc.

Ottawa

2/24/06

C$0.7 ($0.6)

New Generation Biotechnology Funds purchased C$0.7M in convertible debentures and would buy C$0.3M more if certain milestones are reached

Supernus
Pharmaceuticals
Inc.

Rockville, Md.

2/21/06

$17.5

The $17.5 investment closed the Series A financing round at $45M; Supernus raised $27.5M in January; investing in the second closing were New Enterprise Associates and Abingworth Management

Symphony
Medical Inc.

Cleveland

2/28/06

$6

New investor Triathlon Medical Ventures joined existing investors Morgenthaler Ventures, Domain Associates and Guidant Compass Group in the financing round


Notes:
Currency conversions are based on exchange rates at the time of the deal.
ND = Not disclosed.

No Comments